Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study-Reference-Cited by-同舟云学术

Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study

Published:2023-08-25 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Seul Tae Woong¹,Park Hyun Woo¹,Kim Hyo Yoon¹,Shin Jung Jin¹,Son Sang Wook¹

Affiliation:

1. Korea University Ansan Hospital

Abstract

Abstract Long-term data on dupilumab drug survival in Asia patients with atopic dermatitis (AD) are limited. A single-center, retrospective study was performed to assess drug survival between March 2019 and March 2023. Drug survival and associated characteristics were analyzed using Kaplan–Meier survival curves and multivariate Cox regression analysis, respectively. A total of 124 patients with AD (Mean age [standard deviation], 26.0 [8.6] years) with a 4 years-overall dupilumab drug survival rate of 87.9%, were included in this study. During the same period, drug survival in the 479 cyclosporine patients was 0.2%, statistically different from the dupilumab group (p -value < 0.001). Characteristics associated with shorter drug survival were the low eczema area and severity index (EASI) scores at baseline (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.75–0.94, p-value = 0.003) and non-insurance coverage of dupilumab (HR, 11.87; 95% CI, 3.28–42.99, p-value = 0.001). This retrospective study demonstrated good overall 4-year dupilumab survival (87.9%) in South Korea. Patients with low baseline EASI scores and those who did not have insurance for dupilumab treatment discontinued the therapy frequently. To the best of our knowledge, this is the first long-term dupilumab drug survival study conducted in Asia with predictors.

Publisher

Research Square Platform LLC

Reference15 articles.

1. Beck, L. A. et al. Dupilumab treatment in adults with moderate to severe atopic dermatitis. N. Engl. J. Med. 371, 130–139 (2014), PubMed PMID: 25006719.

2. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (Liberty AD CAFE);Bruin-Weller M;Br. J. Dermatol.,2018

3. Guttman-Yassky, E. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 155–172 (2019), PubMed PMID: 30194992.

4. Khosravi, H. et al. Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J. Am. Acad. Dermatol. 82, 1023–1024 (2020), PubMed PMID: 31866263.

5. Napolitano, M. et al. Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicenter study. J. Dermatolog. Treat. 33, 2670–2673 (2022), PubMed PMID: 35435125.